ArticleThe Journal of experimental medicine2006
Are hemostasis and thrombosis two sides of the same coin?
Article in The Journal of experimental medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- micro-RNAs dependent regulation of DNMT and HIF1α gene expression in thrombotic disorders.Scientific reports · 2019Pooled it
- A Neutrophil-like Cell Model as Substitute for Human Neutrophils in NETs and Thrombosis Research.Cells · 2026Article
- Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence.Frontiers in cardiovascular medicine · 2022Review
- Venous and arterial thromboembolism in patients with inflammatory bowel diseases.World journal of gastroenterology · 2021Review
- Platelet Mechanobiology Inspired Microdevices: From Hematological Function Tests to Disease and Drug Screening.Frontiers in pharmacology · 2021Review
- New Antithrombotic Drugs in Acute Coronary Syndrome.Journal of clinical medicine · 2020Review
- Paroxysmal Atrial Fibrillation: Insight Into the Intimate Mechanisms of Coagulation.Cardiology research · 2020Article
- AnBioMed research international · 2020Article
- Early prediction of severity in acute ischemic stroke and transient ischemic attack using platelet parameters and neutrophil-to-lymphocyte ratio.Journal of clinical laboratory analysis · 2019Article
- Inhibitory Effects of Ginsenoside Ro on Clot Retraction through Suppressing PI3K/Akt Signaling Pathway in Human Platelets.Preventive nutrition and food science · 2019Article
- Factor XII (Hageman Factor) Deficiency: a rare harbinger of life threatening complications.The Pan African medical journal · 2019Article
- Thrombosis-on-a-chip: Prospective impact of microphysiological models of vascular thrombosis.Current opinion in biomedical engineering · 2018Article
- Recent advances in hemophilia B therapy.Drug delivery and translational research · 2017Review
- Opposite effects ofAnnals of translational medicine · 2017Article
- The initiation and effects of plasma contact activation: an overview.International journal of hematology · 2017Review
- Volume and Characteristics of Intracerebral Hemorrhage with Direct Oral Anticoagulants in Comparison with Warfarin .Cerebrovascular diseases extra · 2017Article
- Antiplatelet and antithrombotic effects of cordycepin-enriched WIB-801CE from Cordyceps militaris ex vivo, in vivo, and in vitro.BMC complementary and alternative medicine · 2016Article
- New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs).Nutrients · 2015Review
- Development and hemocompatibility testing of nitric oxide releasing polymers using a rabbit model of thrombogenicity.Journal of biomaterials applications · 2014Review
- Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Factor XII (FXII), a clotting enzyme that can initiate coagulation in vitro, has long been considered dispensable for normal blood clotting in vivo because hereditary deficiencies in FXII are not associated with spontaneous or excessive bleeding. However, new studies show that mice lacking FXII are protected against arterial thrombosis (obstructive clot formation) and stroke. Thus, FXII could be a unique drug target that could be blocked to prevent thrombosis without the side effect of increased bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.